Analytical Data
-
Gene name
IL-3R alpha/CD123
- Application
-
Alternative Names
CD123; IL3R-A; IL3RY; IL3RAY; IL3R; IL3RAY; IL3RY; hIL-3Ra
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P26951
-
Expression Region
Thr19~Arg305
-
Molecular Weight
40kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-3 receptor alpha (IL-3Rα), also known as CD123, is a crucial component of the IL-3 receptor complex that plays a significant role in hematopoiesis and immune regulation. This receptor is primarily expressed on hematopoietic stem cells, progenitor cells, and various immune cells, making it a critical target for understanding and treating hematological malignancies and immune disorders. The dysregulation or overexpression of IL-3Rα has been implicated in the pathogenesis of several diseases, including acute myeloid leukemia (AML) and other cancers, where it contributes to the survival and proliferation of malignant cells. The development of recombinant proteins of IL-3Rα/CD123 has opened avenues for targeted therapies, particularly in creating monoclonal antibodies or fusion proteins that can selectively bind to IL-3Rα-expressing cells. Moreover, these studies contribute to a deeper understanding of receptor signaling mechanisms and the potential for using IL-3Rα as a biomarker for disease progression. The ongoing research aims to explore the therapeutic potential of targeting IL-3Rα in combination with other treatments to improve outcomes in patients with hematological malignancies. Thus, the characterization of IL-3Rα/CD123 recombinant proteins is of paramount importance in both basic science and clinical applications, providing insights into new therapeutic strategies while enhancing our understanding of its biological functions in health and disease.
